Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.09.2022 | Case report

Methotrexate/prednisone

Deficiency of humoral response: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Bartoletti A, et al. SEROLOGICAL RESPONSE FOLLOWING THREE DOSES of SARS-COV-2 MRNA VACCINE in PATIENTS with GIANT CELL ARTERITIS: EXPERIENCE of A SINGLE-CENTRE COHORT. Annals of the Rheumatic Diseases 81 (Suppl. 1): 380-381 abstr. POS0275, 23 May 2022. Available from: URL: http://doi.org/10.1136/annrheumdis-2022-eular.4020 [abstract] Bartoletti A, et al. SEROLOGICAL RESPONSE FOLLOWING THREE DOSES of SARS-COV-2 MRNA VACCINE in PATIENTS with GIANT CELL ARTERITIS: EXPERIENCE of A SINGLE-CENTRE COHORT. Annals of the Rheumatic Diseases 81 (Suppl. 1): 380-381 abstr. POS0275, 23 May 2022. Available from: URL: http://​doi.​org/​10.​1136/​annrheumdis-2022-eular.​4020 [abstract]
Metadaten
Titel
Methotrexate/prednisone
Deficiency of humoral response: case report
Publikationsdatum
01.09.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-24091-1

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

COVID-19-vaccine

Case report

Multiple drugs

Case report

Antibacterials

Case report

Multiple drugs

Case report

Multiple drugs